Physician profile
Melissa E Griffith
NPI 1275607178
$6,523.27
in general payments reported to CMS, 2019-2025
37 companies · $889 in 2025
The $889 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,472 · 2022: $1,736 · 2023: $1,266 · 2024: $1,160 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,315.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,539.71 | 2021-2025 | Tezspire, Saphnelo, Fasenra |
| Amgen INC. | $1,037.38 | 2021-2025 | Tezspire, Otezla, Tavneos |
| Glaxosmithkline, LLC. | $890.45 | 2021-2025 | Arexvy, Nucala, Benlysta |
| Abbvie INC. | $296.05 | 2021-2025 | |
| Blueprint Medicines Corporation | $295.00 | 2023-2025 | Ayvakit |
| Ucb, INC. | $214.88 | 2021-2025 | Cimzia, Bimzelx |
| Ani Pharmaceuticals, INC. | $208.77 | 2022-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $196.79 | 2021-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $184.15 | 2021-2024 | Acthar |
| Janssen Biotech, INC. | $166.26 | 2021-2024 | Tremfya, Simponi Aria |
| Horizon Therapeutics Plc | $153.72 | 2021-2023 | Krystexxa |
| Mylan Specialty L.P. | $138.83 | 2021-2024 | Yupelri |
| Lundbeck LLC | $124.98 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.29 | 2022-2025 | Ofev |
| Novartis Pharmaceuticals Corporation | $93.07 | 2021-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $90.48 | 2021-2024 | |
| Sobi, INC | $87.39 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $67.98 | 2024 | Opsumit |
| Genzyme Corporation | $65.09 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $59.92 | 2021 | |
| Alexion Pharmaceuticals, INC. | $51.85 | 2024-2025 | Strensiq, Ultomiris |
| Genentech USA, INC. | $48.61 | 2022 | |
| Tactile Systems Technology INC | $42.74 | 2024 | Entre Plus, Flexitouch Plus |
| Pharming Healthcare, INC. | $42.19 | 2024-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $37.56 | 2021-2023 | Takhzyro |
| Grifols USA, LLC | $35.11 | 2025 | Prolastin-C Liquid |
| Tonix Medicines, INC. | $30.57 | 2025 | Tonmya |
| Biocryst US Sales Co., LLC | $30.54 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $26.18 | 2025 | Dawnzera |
| Lilly USA, LLC | $24.54 | 2021 | |
| Abbott Laboratories | $23.86 | 2022 | |
| Avanos Medical | $22.08 | 2025 | Pnb and Accessories |
| Optinose US, INC. | $17.83 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.44 | 2022 | |
| Organon LLC | $15.17 | 2024 | |
| Sandoz INC. | $13.91 | 2024 | Hyrimoz |
| Ultragenyx Pharmaceutical INC. | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.